Qiagen N.V.(QGEN) Stock Research - Grey Stern Research
Loading...

Qiagen N.V. (QGEN) Stock Analysis

$45.59 (-0.20%)

QGEN Financial Performance


Use the table below to view Qiagen N.V.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $45.68 -
52 Week Low $34.74 -
52 Week High $47.44 -
Market Cap $10.1 Billion 5/13
Gross Margin 6% 13/13
Profit Margin -37% 9/13
EBITDA margin -22% 10/13
Q2 - 2024 Revenue $496.3 Million 5/13
Q2 - 2024 Earnings -$183.5 Million 13/13
Q2 - 2024 Free Cash Flow $127.7 Million 3/13
Trailing 4 Quarters Revenue $1.9 Billion 5/13
Trailing 4 Quarters Earnings $72.7 Million 4/13
Quarterly Earnings Growth -327% 13/13
Annual Earnings Growth -78% 10/13
Quarterly Revenue Growth 0% 10/13
Annual Revenue Growth -1% 10/13
Cash On Hand $533.6 Million 4/13
Short Term Debt $492.7 Million 2/13
Long Term Debt $908.9 Million 7/13

Qiagen N.V. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Qiagen N.V.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 139.40 1/13
PS 5.22 4/13
PB 2.98 7/13
PC 18.99 9/13
Liabilities to Equity 0.64 8/13
ROA 0.01 4/13
ROE 0.02 7/13
Current Ratio 2.56 4/13
Quick Ratio 0.41 7/13
Long Term Debt to Equity 0.27 8/13
Debt to Equity 0.41 6/13
Burn Rate 1.56 9/13
Cash to Cap 0.05 5/13
CCR -0.70 11/13
EV to EBITDA -102.86 10/13
EV to Revenue 5.67 4/13

Company Details

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

CEO: Mr. Thierry Bernard

Website: https://www.qiagen.com

Address: Hulsterweg 82 Venlo, LIMBURG

Exchange: New York Stock Exchange

Industry: Diagnostics & Research

Qiagen N.V. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Qiagen N.V.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Syneos Health, Inc. SYNH $4.5 Billion
IQVIA Holdings Inc. IQV $44.6 Billion
ICON Public Limited Company ICLR $24.9 Billion
Medpace Holdings, Inc. MEDP $11.4 Billion
Aclaris Therapeutics, Inc. ACRS $86.3 Million
NeoGenomics, Inc. NEO $2.1 Billion
Neogen Corporation NEOG $3.8 Billion
Natera, Inc. NTRA $15.7 Billion
Guardant Health, Inc. GH $3.1 Billion
Sotera Health Company SHC $4.7 Billion
Akumin Inc. AKU $26.3 Million
Olink Holding AB (publ) OLK $3.2 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
QGEN Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 496.3 Million -$183.5 Million
Q1 2024 $ 458.8 Million $80.7 Million
Q4 2023 $ 509.2 Million $97.7 Million
Q3 2023 $ 475.9 Million $77.8 Million
Q2 2023 $ 494.9 Million $80.8 Million
Q1 2023 $ 485.4 Million $85.0 Million
Q4 2022 $ 498.0 Million $88.8 Million
Q3 2022 $ 499.6 Million $82.4 Million

View All

QGEN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $533.6 Million $5.6 Billion $1.4 Billion $3.4 Billion
Q1 2024 $513.7 Million $5.8 Billion $1.5 Billion $3.6 Billion
Q4 2023 $668.1 Million $6.1 Billion $1.5 Billion $3.8 Billion
Q3 2023 $579.9 Million $5.9 Billion $1.5 Billion $3.7 Billion
Q2 2023 $609.5 Million $6.3 Billion $1.9 Billion $3.6 Billion
Q1 2023 $359.2 Million $6.3 Billion $1.9 Billion $3.6 Billion
Q4 2022 $730.7 Million $6.3 Billion $1.9 Billion $3.5 Billion
Q3 2022 $1.3 Billion $6.5 Billion $2.3 Billion $3.3 Billion

View All

QGEN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $127.7 Million -$38.9 Million $20.0 Million
Q1 2024 $94.7 Million -$38.4 Million -$154.4 Million
Q4 2023 $99.1 Million -$52.2 Million $88.1 Million
Q3 2023 $83.6 Million -$41.0 Million -$29.6 Million
Q2 2023 $80.3 Million -$31.1 Million $250.4 Million
Q1 2023 $33.5 Million -$38.4 Million -$371.5 Million
Q4 2022 $77.7 Million -$46.6 Million -$540.9 Million
Q3 2022 $184.9 Million -$26.7 Million $565.1 Million

View All